Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ...

COMPASS Pathways shares show an early bullish trend, with a falling-wedge breakout holding key long-term support and setting ...

The psychedelic industry is poised to have a significant "second wave," transforming from a speculative, ...

With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one ...

Gain an autonomous research partner that reveals insights, launches studies, and formulates winning strategies - ...

Trump administration officials vetoed the FDA's plan to fast-track the review of a psychedelic treatment for severe ...

The FDA last year wanted to expedite the review of Compass Pathways’ psilocybin treatment for severe depression as part of a ...

A research-backed roadmap that uses data-driven insights to help learners identify natural strengths, navigate ...

Pfizer announces the first data from its Metsera-acquired pipeline just ahead of its earnings call, where analysts pressed ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not ...

Eli Lilly leapfrogs Novo Nordisk as sales prospects diverge sharply; FTC reaches settlement with Express Scripts over PBM’s ...